Bionik Laboratories (Bionik Laboratories) Short-Term Debt & Capital Lease Obligation : $0.02 Mil (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Bionik Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.02 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Bionik Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $2.39 Mil.

Bionik Laboratories Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Bionik Laboratories's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Short-Term Debt & Capital Lease Obligation Chart

Bionik Laboratories Annual Data

Trend

Dec14

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

2.08

2.61

0.02

Bionik Laboratories Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.02	0.02	0.02

Bionik Laboratories Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Bionik Laboratories Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionik Laboratories (Bionik Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Coolidge Hill Road, Watertown, MA, USA, 02472

Website

https://www.bioniklabs.com

Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.

Executives

Remi Gaston-dreyfus	director, 10 percent owner	46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine	director	7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve	director, officer: Chairman	18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves	officer: Executive Vice President & CFO	80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass	officer: See Remarks	34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin	director
Audrey Thevenon	director	4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone	director
Russo Richard Paul Jr	officer: Chief Financial Officer	20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy	officer: Chief Commercialization Office	C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux	director	1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried	officer: VP - U.S. Operations	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs	officer: Chief Science Officer	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu	director	716 BROOKS AVENUE, VENICE CA 90291